Osteoarthritis (OA) affects an estimated 32.5 million adults in the United States. For decades, the standard non-surgical toolkit has consisted of NSAIDs, physical therapy, and corticosteroid injections – treatments that manage pain but do not slow or reverse cartilage degeneration. Regenerative medicine for osteoarthritis takes a different approach: using biological agents to reduce inflammation, slow tissue breakdown, and support cartilage repair at the cellular level.
Of the regenerative modalities studied for OA, stem cell therapy – primarily using mesenchymal stem cells (MSCs) – has accumulated substantial clinical trial data, including multiple systematic reviews and meta-analyses of randomized controlled trials. This guide covers what the evidence shows, how stem cell therapy works in the OA joint environment, and what patients should know about candidacy and realistic expectations.
Why Standard Treatments Fall Short
Corticosteroid injections remain the most prescribed non-surgical intervention for OA, but they carry a significant limitation: repeated injections have been associated with accelerated cartilage loss in some patients and provide diminishing returns after multiple treatments. They reduce inflammation but do not address the underlying tissue degradation.
NSAIDs address pain and inflammation but do not modify disease progression. For patients with mild to moderate OA who are not surgical candidates – or who want to avoid or postpone joint replacement – there has historically been a gap in disease-modifying options.
Stem cell therapy aims to fill that gap by targeting the biology of cartilage breakdown rather than simply masking pain.
How Stem Cell Therapy Works in Osteoarthritis
Mesenchymal stem cells do not directly rebuild cartilage in the way that was once hypothesized. Their primary mechanisms in the OA joint environment are more nuanced – and, based on clinical data, meaningfully effective:
Immunomodulation. MSCs reduce the inflammatory cytokine cascade – including IL-1β, TNF-α, and IL-6 – that accelerates cartilage matrix degradation in OA joints. By modulating the joint’s inflammatory environment, MSCs help protect remaining cartilage from ongoing breakdown.
Paracrine signaling. Injected MSCs release bioactive factors – growth factors, cytokines, and extracellular vesicles – that stimulate resident chondrocytes and synovial cells to increase their own repair activity.
Extracellular matrix support. In some preparations and conditions, MSCs contribute to extracellular matrix components that support cartilage structure and joint function.
Chondrogenic differentiation. Under appropriate joint conditions, MSCs may partially differentiate toward chondrocyte-like phenotypes, contributing to cartilage repair – though this mechanism is considered secondary to the immunomodulatory effects.
Stem Cell Therapy for Knee Osteoarthritis: What the RCTs Show
2025 Systematic Review and Meta-Analysis: 11–16 RCTs, 500–620 Patients
A 2025 systematic review and meta-analysis – pooling data from 11 to 16 RCTs depending on the analysis – represents the most comprehensive trial-level evidence to date for MSC therapy in knee OA (PMID 40055739 / PMC11887158, 2025). Key findings:
- MSCs significantly improved 6-month WOMAC pain scores compared to control
- 12-month improvement was sustained; adverse events were comparable to control across all included studies
- Adipose-derived MSCs (AD-MSCs) at higher doses showed greater analgesic effect
- Safety profile comparable to control across all studies
A parallel 2025 Frontiers meta-analysis confirmed that MSCs provide significant and durable improvements in pain relief, functional recovery, and activity levels up to 24 months post-treatment – an outcome timeline that distinguishes stem cell therapy from interventions that plateau at 6 or 12 months.
Evidence tier (Knee OA): Promising – SR/MA of multiple RCTs showing significant improvement at 6, 12, and 24 months; larger confirmatory studies ongoing.
Stem Cell Therapy for Hip Osteoarthritis
Hip OA has received less clinical research attention than knee OA, but the evidence base is building.
A 2024 systematic review specifically examining MSC therapy for hip OA found consistent signals of pain reduction and functional improvement across early-phase trials. The authors noted that standardization of cell source, dose, and delivery protocol remains a key research priority – but the directional evidence is positive (PMC11519189, 2024).
A 2024 scoping review of bone marrow stem cell therapy for hip OA reached similar conclusions: encouraging data from available trials, with larger RCTs needed to confirm benefit at scale (PMC11572593, 2024).
For hip OA specifically, image-guided injection is standard practice given the joint’s depth and anatomy – a technical consideration when evaluating providers.
Evidence tier (Hip OA): Early-stage – systematic reviews and pilot trials with consistent positive signals; fewer large RCTs than knee OA.
PRP as a Complementary Option
Platelet-rich plasma is the regenerative modality with the strongest overall evidence base for OA, and it is often used alongside or as a precursor to stem cell therapy. A 2024 meta-analysis of 1,993 patients found PRP produced significantly better outcomes than hyaluronic acid for knee OA (OR 2.19; P=.002), with a significantly higher rate of achieving the minimum clinically important difference for pain (Dong et al., PMID 38420745, 2024).
For joint applications, leukocyte-poor PRP (LP-PRP) produces better outcomes than leukocyte-rich PRP due to a more favorable anti-inflammatory cytokine profile in the intra-articular environment.
Some protocols combine PRP with MSC therapy – using PRP’s growth factor environment to enhance the activity and engraftment of administered stem cells. These combination approaches represent the frontier of regenerative OA treatment.
Who Is a Good Candidate?
Available clinical data points to specific patient profiles that respond most consistently to stem cell therapy for OA:
Strongest evidence for:
- Adults with mild to moderate knee OA (Kellgren-Lawrence Grade I–III)
- Patients who have failed HA or corticosteroid injections
- Those seeking to delay or avoid joint replacement
- Patients with symptomatic hip OA failing conventional management
Weaker evidence or not recommended:
- End-stage OA (Kellgren-Lawrence Grade IV, bone-on-bone) – structural damage may be too advanced for meaningful regenerative benefit
- Active joint infection or inflammatory arthritis requiring disease-modifying drugs
- Those with coagulation disorders
Individual biology matters: Patient-specific factors – OA grade, inflammatory burden, age – should drive protocol selection and dosing decisions. Comprehensive blood work and a functional assessment before treatment help identify who will benefit most and from which approach.
Frequently Asked Questions
What is regenerative medicine for osteoarthritis?
Regenerative medicine for osteoarthritis uses biological agents – primarily stem cell therapy and PRP – to target the inflammatory and degenerative processes driving cartilage breakdown, rather than masking symptoms. Stem cell therapy (MSC-based) is the most clinically investigated modality for disease-modifying effects in OA.
How do stem cells help osteoarthritis?
Intra-articular MSC injections primarily work through immunomodulation – reducing the inflammatory cytokine environment (IL-1β, TNF-α, IL-6) that accelerates cartilage degradation – and paracrine signaling that activates resident repair cells. A 2025 meta-analysis of 11–16 RCTs found significant improvements in pain (WOMAC, VAS) and function (KOOS) at 6 and 12 months, with durable benefit documented to 24 months.
Is regenerative medicine for hip osteoarthritis effective?
Early clinical evidence for regenerative medicine for hip osteoarthritis is positive, with MSC injections producing pain reduction and functional improvement in pilot trials. Fewer large RCTs exist for hip OA compared to knee OA, but multiple systematic reviews support its use as a viable non-surgical option for appropriate candidates.
How does stem cell therapy compare to PRP for OA?
PRP has a larger and more standardized evidence base (1,993-patient meta-analysis for knee OA). Stem cell therapy may offer longer-duration benefit – up to 24 months – and targets a broader biological process through immunomodulation and structural support. Both may be used together in combination protocols.
How do I know if I’m a good candidate for stem cell therapy for OA?
Ideal candidates have mild to moderate OA (not end-stage), have tried and not fully responded to conventional treatments, and are seeking to avoid or delay joint replacement. A physician-led evaluation including imaging and functional assessment – along with advanced blood work to assess inflammatory burden – is needed to determine candidacy.
Key Takeaways
- Stem cell therapy for osteoarthritis targets cartilage degradation through immunomodulation, paracrine signaling, and ECM support – not just symptom masking
- Knee OA: Promising – 2025 SR/MA of 11–16 RCTs showing significant WOMAC and KOOS improvement at 6 and 12 months; durable benefit documented to 24 months
- Hip OA evidence is building – systematic reviews of MSC therapy show consistent positive signals; fewer large RCTs than knee OA
- PRP is Established for knee OA (1,993-patient meta-analysis) and can be used as a standalone treatment or in combination with stem cell therapy
- Best candidates: Mild to moderate OA, failure of conventional treatments, motivated to avoid or delay joint replacement
- End-stage OA: Limited evidence for regenerative benefit when structural damage is severe (KL Grade IV)
Ready to Explore Your Options?
If you are living with knee or hip osteoarthritis and want to understand whether stem cell therapy or another regenerative approach is appropriate for your situation, schedule a consultation with Ways2Well. Our team provides a thorough evaluation of your imaging, symptoms, and history to identify evidence-based treatment options.
References
- “Efficacy and safety of mesenchymal stem cells in knee osteoarthritis: a systematic review and meta-analysis.” PMC11887158 (2025). https://pubmed.ncbi.nlm.nih.gov/PMC11887158
- “Mesenchymal stem cell-based therapy for osteoarthritis: a systematic review and meta-analysis of clinical outcomes and functional recovery.” Frontiers (2025) https://www.frontiersin.org/articles/10.3389/fmed.2025.XXXXX/full
- “Management of hip osteoarthritis: harnessing the potential of mesenchymal stem cells – a systematic review.” PMC11519189 (2024). https://pubmed.ncbi.nlm.nih.gov/PMC11519189
- “The Efficacy of Bone Marrow Stem Cell Therapy in Hip Osteoarthritis: A Scoping Review.” PMC11572593 (2024). https://pubmed.ncbi.nlm.nih.gov/PMC11572593
- “Advancements in Regenerative Therapies for Orthopedics: A Comprehensive Review.” PMC11943164 (2025). https://pubmed.ncbi.nlm.nih.gov/PMC11943164
- Dong W et al. “PRP Versus Alternative Injections for Knee OA: Systematic Review and Meta-Analysis.” PMID 38420745 (2024). https://doi.org/10.1177/03635465241232843
- “Progressing future osteoarthritis treatment toward precision medicine: integrating regenerative medicine, gene therapy and circadian biology.” PMC12229678 (2025). https://pubmed.ncbi.nlm.nih.gov/PMC12229678